// App-Quantinova.ai

P255 : Secukinumab provides sustained improvement in nail psoriasis and inhibition of radiographic progression in PsA patients with nail phenotype: 52-week results from a Phase 3 study

Researchers

Presenter

  • Bruce Kirkham

Principal Investigators

  • Peter Nash

  • Philip J Mease

  • Alejandro C Balsa

  • Atul Singhal

  • Erhard Quebe-Fehling

  • Luminita Pricop

  • Corine Gaillez

Medical Centers

  • School of Medicine, Griffith University, Brisbane QLD, AUSTRALIA

  • Rheumatology Department, Swedish Medical Centre and University of Washington, Seattle, WA, USA

  • Rheumatology, Hospital Universitario La Paz - IdiPAZ, Madrid, SPAIN

  • Southwest Rheumatology, Dallas, TX

  • Global Medical Affairs Biostatistics in Global Drug Development, Novartis Pharma AG, Basel, SWITZERLAND

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Australia

  • United States

  • Spain

  • Switzerland

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Dactylitis

  • Psoriasis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02404350

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved